The lab meeting involved discussing the T7E1 assay method for detecting off-target effects of CRISPR/Cas9 genome editing. They aimed to determine the sensitivity, specificity, and ability to detect off-targets in different cell types. The T7E1 assay involves PCR amplification of potential off-target sites followed by cleavage with the T7E1 endonuclease which recognizes mismatches, to indicate editing at off-target locations. They also discussed how enhancing homologous recombination during gene therapy could promote use of the preferred HR repair pathway over non-homologous end joining.